Investors in cash trouble should check out Repligen Corporation (RGEN)

Repligen Corporation (NASDAQ: RGEN) stock jumped 1.99% on Tuesday to $170.05 against a previous-day closing price of $166.74. With 0.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.55 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $171.96 whereas the lowest price it dropped to was $166.53. The 52-week range on RGEN shows that it touched its highest point at $262.26 and its lowest point at $137.65 during that stretch. It currently has a 1-year price target of $200.73. Beta for the stock currently stands at 1.06.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RGEN was up-trending over the past week, with a rise of 11.99%, but this was up by 1.10% over a month. Three-month performance surged to 0.04% while six-month performance fell -3.34%. The stock gained 10.04% in the past year, while it has gained 0.44% so far this year. A look at the trailing 12-month EPS for RGEN yields 2.94 with Next year EPS estimates of 2.98. For the next quarter, that number is 0.49. This implies an EPS growth rate of 44.80% for this year and 26.23% for next year. EPS is expected to grow by 4.29% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 46.60%.

Float and Shares Shorts:

At present, 55.59 million RGEN shares are outstanding with a float of 55.31 million shares on hand for trading. On Apr 27, 2023, short shares totaled 5.36 million, which was 9.64% higher than short shares on Mar 30, 2023. In addition to Mr. Anthony J. Hunt as the firm’s Pres, CEO & Director, Mr. Jon K. Snodgres serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 97.79% of RGEN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 63.66% of RGEN, in contrast to 38.71% held by mutual funds. Shares owned by individuals account for 26.17%. As the largest shareholder in RGEN with 9.24% of the stake, The Vanguard Group, Inc. holds 5,131,246 shares worth 5,131,246. A second-largest stockholder of RGEN, T. Rowe Price Associates, Inc., holds 5,070,657 shares, controlling over 9.13% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in RGEN, holding 4,924,208 shares or 8.86% stake. With a 4.46% stake in RGEN, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,476,781 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.95% of RGEN stock, is the second-largest Mutual Fund holder. It holds 1,636,067 shares valued at 248.08 million. iShares Core S&P Mid Cap ETF holds 2.90% of the stake in RGEN, owning 1,611,354 shares worth 244.33 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, RGEN reported revenue of $207.63M and operating income of $56.28M. The EBITDA in the recently reported quarter was $64.53M and diluted EPS was $0.88.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RGEN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RGEN analysts setting a high price target of $250.00 and a low target of $157.00, the average target price over the next 12 months is $202.33. Based on these targets, RGEN could surge 47.02% to reach the target high and fall by -7.67% to reach the target low. Reaching the average price target will result in a growth of 18.98% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded RGEN stock several times over the past three months with 10 Buys and 17 Sells. In these transactions, 71,494 shares were bought while 30,681 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 41 over the past year. The total number of shares bought during that period was 141,714 while 146,917 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *